Literature DB >> 27473587

Clinical Significance of Histone Demethylase NO66 in Invasive Colorectal Cancer.

Yujiro Nishizawa1, Naohiro Nishida2, Masamitsu Konno2, Koichi Kawamoto1, Ayumu Asai3, Jun Koseki3, Hidekazu Takahashi1, Naotsugu Haraguchi1, Junichi Nishimura1, Taishi Hata1, Chu Matsuda1, Tsunekazu Mizushima1, Taroh Satoh2, Yuichiro Doki1, Masaki Mori4, Hideshi Ishii5,6.   

Abstract

BACKGROUND: Targeting epigenetic regulators is a promising therapeutic strategy against cancer. However, because of the broad spectrum of targets, selective inhibition of cancer-associated genes remains a major challenge. To address this issue, we focused on the oncogene-regulated histone demethylase, nucleolar protein 66 (NO66 [C14orf169/MAPJD]), which is known to work coordinately with the well-characterized oncogene, c-MYC.
METHODS: To investigate expression patterns and clinical significance of NO66 in colorectal cancer (CRC), we performed immunohistochemical staining in 114 CRC cases. We performed functional analysis of NO66 to evaluate its contribution to proliferation and migration ability in CRC cells in vitro.
RESULTS: NO66 was selectively expressed in CRC tissues. Furthermore, high expression levels of NO66 were associated with cancer metastatic potential, including lymphatic duct invasion (p = 0.047), venous invasion (p = 0.033), and lymph node metastasis (p = 0.015). Multivariate analysis indicated that NO66 was an independent prognostic factor for overall survival. In vitro assays revealed that NO66 expression is closely associated with malignant potential, including proliferation, migration and anti-apoptotic activity.
CONCLUSIONS: NO66 is an independent prognostic factor in CRC. The cancer-selective expression patterns and its involvement in metastatic phenotypes suggest that NO66 is not only a crucial biomarker but is also a promising therapeutic target in CRC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27473587     DOI: 10.1245/s10434-016-5395-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  The small members of the JMJD protein family: Enzymatic jewels or jinxes?

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

2.  Essential function and targets of BMP signaling during midbrain neural crest delamination.

Authors:  Michael L Piacentino; Erica J Hutchins; Marianne E Bronner
Journal:  Dev Biol       Date:  2021-06-06       Impact factor: 3.148

Review 3.  The emerging roles of ribosomal histidyl hydroxylases in cell biology, physiology and disease.

Authors:  James R Bundred; Eline Hendrix; Mathew L Coleman
Journal:  Cell Mol Life Sci       Date:  2018-08-27       Impact factor: 9.261

4.  Phylogenetic and genomic analyses of the ribosomal oxygenases Riox1 (No66) and Riox2 (Mina53) provide new insights into their evolution.

Authors:  Katharina E Bräuer; Kevin Brockers; Jasmin Moneer; Annette Feuchtinger; Evi Wollscheid-Lengeling; Andreas Lengeling; Alexander Wolf
Journal:  BMC Evol Biol       Date:  2018-06-19       Impact factor: 3.260

Review 5.  DNA mismatch repair in the context of chromatin.

Authors:  Yaping Huang; Guo-Min Li
Journal:  Cell Biosci       Date:  2020-02-03       Impact factor: 7.133

6.  First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.

Authors:  Radosław P Nowak; Anthony Tumber; Eline Hendrix; Mohammad Salik Zeya Ansari; Manuela Sabatino; Lorenzo Antonini; Regina Andrijes; Eidarus Salah; Nicola Mautone; Francesca Romana Pellegrini; Klemensas Simelis; Akane Kawamura; Catrine Johansson; Daniela Passeri; Roberto Pellicciari; Alessia Ciogli; Donatella Del Bufalo; Rino Ragno; Mathew L Coleman; Daniela Trisciuoglio; Antonello Mai; Udo Oppermann; Christopher J Schofield; Dante Rotili
Journal:  J Med Chem       Date:  2021-11-29       Impact factor: 7.446

7.  Weighted Correlation Network Analysis of Cancer Stem Cell-Related Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma.

Authors:  Mengnan Zhao; Xing Jin; Zhencong Chen; Huan Zhang; Cheng Zhan; Hao Wang; Qun Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.